These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37983691)

  • 21. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
    Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
    Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.
    Delmas PD; Eastell R; Garnero P; Seibel MJ; Stepan J;
    Osteoporos Int; 2000; 11 Suppl 6():S2-17. PubMed ID: 11193237
    [No Abstract]   [Full Text] [Related]  

  • 23. [Innovations in the treatment of osteoporosis].
    Tsourdi E; Hofbauer LC
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
    [No Abstract]   [Full Text] [Related]  

  • 24. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
    van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
    Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postmenopausal osteoporosis: another approach to management.
    Cole R
    J Fam Pract; 2010 Jun; 59(6):E1-7. PubMed ID: 20544058
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
    Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
    Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
    Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial.
    Silverman SL; Nasser K; Nattrass S; Drinkwater B
    Osteoporos Int; 2012 Mar; 23(3):1069-74. PubMed ID: 21755401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
    Baxter I; Rogers A; Eastell R; Peel N
    Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
    Chesnut CH
    Drugs; 2006; 66(10):1351-9. PubMed ID: 16903769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
    Fontalis A; Eastell R
    Bone; 2020 Jul; 136():115336. PubMed ID: 32234415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
    Reginster JY; Malaise O; Neuprez A; Jouret VE; Close P
    Drugs Aging; 2007; 24(5):351-9. PubMed ID: 17503893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate therapy for secondary osteoporosis: adult perspective.
    Reid IR
    Horm Res Paediatr; 2011; 76 Suppl 1():28-32. PubMed ID: 21778745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.